ClinicalTrials.gg
CompletedNCT02172235Updated Jun 24, 2014

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

A Phase 1 interventional study of Pioglitazone and Pioglitazone - low dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-24.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The objective was to investigate the effect of different doses of BI 10773 on the bioavailability of pioglitazone after multiple oral doses of both drugs

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the following criteria:

    medical history, physical examination, vital signs ((blood pressure (BP), pulse rate (PR), 12-lead (ECG)), clinical laboratory tests

  2. Age 18 to 55 years (incl.)
  3. 18.5 to 29.9 kg/m2 (incl.)
  4. Signed and dated written prior to admission to the study in accordance with Good Clinical Practise (GCP) and the local legislation

Exclusion criteria

Exclusion Criteria:

  1. Any finding of the medical examination including blood pressure (BP), pulse rate (PR) and (ECG) deviating from normal and of clinical relevance
  2. Any evidence of a concomitant disease
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  4. Surgery of the gastrointestinal tract (except appendectomy)
  5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  6. History of relevant orthostatic hypotension, fainting spells or blackouts.
  7. Chronic or relevant acute infections
  8. History of relevant allergy/ (including allergy to drug or its )
  9. Intake of drugs with a long half-life (more than 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  10. Participation in another trial with an drug within two months prior to administration or during the trial
  11. Smoker (more than 10 cigarettes or more than 3 cigars or more than 3 pipes/day)
  12. Inability to refrain from smoking on trial days
  13. Alcohol abuse (more than 30 g/day)
  14. Drug abuse
  15. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  16. Excessive physical activities (within one week prior to administration or during the trial)
  17. (ALT) outside the normal range or any other laboratory value outside the reference range that is of clinical relevance
  18. Inability to comply with dietary regimen of trial site
  19. Galactose or lactose intolerance, galactose or glucose malabsorption
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Pioglitazone

    Drug: Pioglitazone

  • Experimental
    Pioglitazone + BI 10773 low

    Drug: Pioglitazone · Drug: BI 10773 - low dose

  • Experimental
    Pioglitazone + BI 10773 medium

    Drug: Pioglitazone · Drug: BI 10773 - medium dose

  • Experimental
    Pioglitazone + BI 10773 high

    Drug: Pioglitazone · Drug: BI 10773 - high dose

  • Experimental
    Pioglitazone low + BI 10773 medium

    Drug: Pioglitazone - low dose · Drug: BI 10773 - medium dose

  • Experimental
    Pioglitazone + BI 10773 1 hour after Pioglitazone

    Drug: Pioglitazone · Drug: BI 10773 - medium dose

Interventions

06

What researchers measure

Primary outcomes

  1. AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: Before each dosing, up to 10 days

  2. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: Before each dosing, up to 10 days

Secondary outcomes

  1. C24,N (concentration of the analyte in plasma at 24 h after administration of the Nth dose)

    Time frame: Before each dosing, up to 10 days

  2. λz (terminal elimination rate constant of the analyte in plasma)

    Time frame: Before each dosing, up to 10 days

  3. t½ (terminal half-life of the analyte in plasma)

    Time frame: Before each dosing, up to 10 days

  4. tmax (time from last dosing to maximum measured concentration of the analyte in plasma)

    Time frame: Before each dosing, up to 10 days

  5. MRTpo (mean residence time of the analyte in the body at steady state after oral administration)

    Time frame: Before each dosing, up to 10 days

  6. CL/F (apparent clearance of the analyte in the plasma after extravascular administration)

    Time frame: Before each dosing, up to 10 days

  7. Vz/F (apparent volume of distribution during the terminal phase λz following extravascular administration)

    Time frame: Before each dosing, up to 10 days

  8. Aet1-t2 (amount of analyte eliminated in urine over the time interval t1 to t2 )

    Time frame: Day1 (-1-0, 0-4, 4-8, 8-12, and 12-24 h), Day 7 (143-144, 144-148, 148-152, 152-156, and 156-168 h)

  9. fet1-t2 (fraction of dose excreted unchanged in urine over the time interval t1 to t2)

    Time frame: Day1 (-1-0, 0-4, 4-8, 8-12, and 12-24 h), Day 7 (143-144, 144-148, 148-152, 152-156, and 156-168 h)

  10. CLR (renal clearance of the analyte in plasma afer extravascular administration)

    Time frame: Day1 (-1-0, 0-4, 4-8, 8-12, and 12-24 h), Day 7 (143-144, 144-148, 148-152, 152-156, and 156-168 h)

  11. Cmax (maximum concentration of the analyte in plasma)

    Time frame: Before each dosing, up to 10 days

  12. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable plasma concentration)

    Time frame: Before each dosing, up to 10 days

  13. AUCτ,1 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable plasma concentration within the first dosing interval)

    Time frame: Before each dosing, up to 10 days

  14. AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: Before each dosing, up to 10 days

  15. Metabolite to parent ratio

    Time frame: Before each dosing, up to 10 days

  16. Number of patients with abnormal findings in physical examination

    Time frame: up to 30 days after drug administration

  17. Number of patients with abnormal changes in laboratory parameters

    Time frame: up to 30 days after drug administration

  18. Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)

    Time frame: up to 30 days after drug administration

  19. Number of patients with clinically significant changes in vital signs

    Time frame: up to 30 days after drug administration

  20. Assessment of tolerability by investigator on a 4-point scale

    Time frame: up to 10 days

  21. Number of patients with adverse events

    Time frame: up to 51 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010 and a primary completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 24, 2014
Start
Apr 2010
Primary completionActual
Jul 2010
Last update
Jun 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02172235
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
Apr 2010
Primary completion
Jul 2010
Last update
Jun 24, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Empagliflozin

Start the discussion